Introduction
Vitamin D deficiency is consistently reported to be more common in patients with chronic obstructive pulmonary disease (COPD) than in healthy controls (1) (2) (3) , and is associated with reduced forced expiratory volume in one second (FEV 1 ) (3) (4) (5) (6) (7) (8) , forced vital capacity (FVC), peak expiratory flow (PEF), respiratory quality of life (QoL) (4), increased daily inhaled corticosteroid (ICS) dose and hypoxaemia (8) . Findings from studies which have investigated the impact of vitamin D status on exercise capacity or skeletal muscle strength are conflicting, with some studies reporting inverse associations (6, 9) and others studies reporting null effects (7, 10) .
In a recent clinical trial we found vitamin D supplementation to significantly reduce risk of COPD exacerbation in those who were deficient at baseline (<50 nmol/L) (11) . However the determinants of vitamin D deficiency in COPD patients, and the clinical correlates of disease severity are not well defined: raised neutrophil and eosinophil counts and increased concentrations of inflammatory mediators secreted by these cells have been identified in the lower airways during COPD exacerbation (12) (13) (14) , but to our knowledge, there are no previous cross-sectional investigations of serum 25(OH)D concentration and differential white cell counts in induced sputum in patients with COPD. Furthermore, environmental and genetic factors which have been shown to influence vitamin D status in healthy populations (15, 16) have not yet been well characterised in COPD patients, nor have genetic factors which may associate with clinical markers of COPD severity.
We therefore conducted a cross-sectional analysis to determine the prevalence of vitamin D deficiency in COPD patients living in London, UK, and to identify genetic and environmental determinants of vitamin D status in this group. We also conducted analyses to explore whether vitamin D status or genetic variation in the vitamin D pathway associated with any clinical features of COPD, either independently or in interaction with each other.
Methods

Participants
Adult patients with a medical record diagnosis of COPD, emphysema or chronic bronchitis were identified by database searches at 60 general practices and COPD clinics in 4 Acute National Health Service Trusts in London, UK, and invited for screening as previously described (11) . The study was approved by East London and The City Research Ethics Committee 1 (ref 09/H0703/76) and written informed consent was obtained from all participants before enrolment.
Procedures
Respondents were asked to complete a lifestyle questionnaire detailing age, sex, ethnicity, self-reported Another sub-set of 44 participants underwent sputum induction with hypertonic saline, and their samples were processed to make cytospin slides according to methods described by Pizzichini et al (22) . Participants'
COPD severity was categorised according to Global Initiative on Obstructive Lung Disease (GOLD) stages:
mild/GOLD stage 1 (FEV 1 ≥80%), moderate/GOLD stage 2 (FEV 1 50-79%), severe/GOLD stage 3 (FEV 1 30-49%), and very severe/GOLD stage 4 (FEV 1 <30%).
Single nucleotide polymorphism panel selection
A literature search of the PubMed database was performed to identify SNP previously shown to associate with serum 25(OH)D concentration and/or non-skeletal disease, described here (23). We identified 55 such SNP in 11 genes in the vitamin D pathway. Based on linkage disequilibrium (LD) relationships between these SNP, we selected 6 tagging SNP (tSNP) (24), using a r 2 threshold of 0.8, which reduced the number of genotyped SNP to 37.
Laboratory analyses
Serum concentrations of 25(OH)D 2 and 25(OH)D 3 were determined by isotope-dilution liquid chromatographytandem mass spectrometry (14) in the Department of Clinical Biochemistry at Homerton Hospital, and summed to give total serum 25(OH)D concentration. This laboratory participates in the international vitamin D external quality assurance scheme (www.deqas.org/). PTH concentrations were determined using an Architect ci8200 analyser (Abbott Diagnostics, Chicago, IL, USA). DNA was extracted from whole blood using a saltingout method (15) on the Biomek FX robot (Beckman Coulter), quantified using the Nanodrop spectrophotometer and normalised to 5ng/µl. 10ng DNA were used as template for 2 µl TaqMan assays (Applied Biosystems, Foster City, CA, USA) performed on the ABI 7900HT platform in 384-well format and analysed with Autocaller software as previously described (25). Typing for two SNP failed (rs6127118, CYP24A1
and rs11574010, VDR). 
Statistical analyses
Results
Study population
Environmental determinants of serum 25(OH)D concentration
Environmental determinants of vitamin D status are presented in 
Genetic determinants of serum 25(OH)D concentration
Genetic determinants of vitamin D status are presented in (Table S1 ), quadriceps strength (Table S2) , St.
George's respiratory questionnaire score (Table S3) , daily inhaled corticosteroid dose (Table S4) , percentage of eosinophils in sputum (Table S5) , or percentage of neutrophils in sputum (Table S6) .
Multiple linear regression analysis revealed several other factors to independently associate with various clinical features of COPD. Higher % predicted FEV 1 associated with higher BMI ( 
Association between genetic factors and clinical correlates of COPD severity
Genetic determinants of clinical correlates of COPD severity are presented in Table S7 (FEV 1 ), Table S8 (FVC), 
Discussion
To our knowledge this study represents the most comprehensive cross-sectional analysis of environmental and 
Study strengths
Our study has several strengths. We characterised our patients in a considerable level of detail which allowed us to investigate a wide range of potential genetic and environmental determinants of vitamin D status, and to control for a wide range of potential factors which may confound the relationship between vitamin D status and markers of COPD severity. Spirometry was performed using international guidelines and serum 25(OH)D concentrations were measured with the gold standard assay (LC-MS/MS) in a laboratory that participated in the international vitamin D external quality assurance scheme (www.deqas.org/). Our study population included COPD patients with a range of disease severity, who were recruited in both community and hospital settings and across all four seasons -all of which are factors that enhance the generalisibility of our results.
Finally, to our knowledge, this was the first study of COPD patients to investigate a cross-sectional relationship between vitamin D status and sputum biomarkers.
Study limitations
Our study also has some limitations. Due to the high prevalence of vitamin D deficiency in our cohort only a little over 10% of participants had a serum 25(OH)D concentration >75 nmol/L: we may therefore have been underpowered to detect associations between the highest serum concentrations of 25(OH)D and clinical correlates of COPD severity. Type 2 error as a result of limited power may also have been an issue in our analysis of quadriceps strength, which was conducted in a subset of 134 patients, and sputum markers of COPD severity, which was conducted in a subset of 44 patients, and it may have prevented us from detecting modest effects of genetic variation on vitamin D status and disease severity.
In conclusion, our findings highlight a high prevalence of vitamin D deficiency in a UK population of COPD patients, which was independently associated with reduced % predicted FEV1 and % predicted FVC. Vitamin D deficiency was associated with classical environmental determinants as reported in healthy populations, but not with genetic variation in the vitamin D pathway. Our findings will help clinicians to identify COPD patients who are at particular risk of vitamin D deficiency, and allow correction of deficiency where appropriate -an intervention that has now been shown to reduce risk of COPD exacerbations in two clinical trials (11, 27) . 1 
